Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MHB088C in Advanced Extrapulmonary Neuroendocrine Cancer
NCT06951243Phase 2Not yet recruiting
- Sponsor
- Beijing Gaobo Hospital
- Start
- May 2025
- Primary completion
- May 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
01
Overview
A Phase 2 trial of MHB088C in extrapulmonary neuroendocrine carcinoma (EPNEC), sponsored by Beijing Gaobo Hospital. Planned start May 2025; status: not yet recruiting.
02
Drugs
MHB088C
03
Conditions
extrapulmonary neuroendocrine carcinoma (EPNEC)
Beyond the preview
Go deeper on NCT06951243.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06951243.